Sumoylation of Vimentin354 is Associated with PIAS3 Inhibition of Glioma Cell Migration

Overview

Journal Oncotarget

Specialty Oncology

Date 2011 Feb 15

PMID 21317457

Citations 20

Authors

Liming Wang

Jian Zhang

Sipra Banerjee

Laura Barnes

Venkateswara Sajja

Yiding Liu

Baochuan Guo

Yuping Du

Mukesh K Agarwal

David N Wald

Qin Wang

Jinbo Yang

Affiliations

Soon will be listed here.

Abstract

The invasive phenotype of glioblastoma multiforme (GBM) is a hallmark of malignant process, yet the molecular mechanisms that dictate this locally invasive behavior remain poorly understood. Over-expression of PIAS3 effectively changes cell shape and inhibits GBM cell migration. We focused on the molecular target(s) of PIAS3 stimulated sumoylation, which play an important role in the inhibition of GBM cell motility. Here we report, through the immunoprecipitation with SUMO1 antibody, followed by proteomic analysis, the identification of vimentin (vimentin354), a nuclear component in GBM cells, as the main target of sumoylation promoted by PIAS3.

Citing Articles

Cancer-Associated Dysregulation of Sumo Regulators: Proteases and Ligases.

Lara-Urena N, Jafari V, Garcia-Dominguez M Int J Mol Sci. 2022; 23(14).

PMID: 35887358 PMC: 9316396. DOI: 10.3390/ijms23148012.

Pathophysiological Role of Vimentin Intermediate Filaments in Lung Diseases.

Surolia R, Antony V Front Cell Dev Biol. 2022; 10:872759.

PMID: 35573702 PMC: 9096236. DOI: 10.3389/fcell.2022.872759.

The "Third Violin" in the Cytoskeleton Orchestra-The Role of Intermediate Filaments in the Endothelial Cell's Life.

Shakhov A, Alieva I Biomedicines. 2022; 10(4).

PMID: 35453578 PMC: 9027429. DOI: 10.3390/biomedicines10040828.

Impact of Vimentin on Regulation of Cell Signaling and Matrix Remodeling.

Ostrowska-Podhorodecka Z, Ding I, Norouzi M, McCulloch C Front Cell Dev Biol. 2022; 10:869069.

PMID: 35359446 PMC: 8961691. DOI: 10.3389/fcell.2022.869069.

Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics.

Krishna A, John S, Shinde P, Mishra R Cancer Cell Int. 2021; 21(1):575.

PMID: 34715855 PMC: 8555349. DOI: 10.1186/s12935-021-02279-y.

References

Wible B, Wang L, Kuryshev Y, Basu A, Haldar S, Brown A . Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. J Biol Chem. 2002; 277(20):17852-62. DOI: 10.1074/jbc.M201689200. View

Reinhardt A, Hubbard T . Using neural networks for prediction of the subcellular location of proteins. Nucleic Acids Res. 1998; 26(9):2230-6. PMC: 147531. DOI: 10.1093/nar/26.9.2230. View

Hoelzinger D, Mariani L, Weis J, Woyke T, Berens T, McDonough W . Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. Neoplasia. 2005; 7(1):7-16. PMC: 1490313. DOI: 10.1593/neo.04535. View

Chung C, Liao J, Liu B, Rao X, Jay P, Berta P . Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997; 278(5344):1803-5. DOI: 10.1126/science.278.5344.1803. View

Shiras A, Bhosale A, Shepal V, Shukla R, Baburao V, Prabhakara K . A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers. Neoplasia. 2004; 5(6):520-32. PMC: 1502577. DOI: 10.1016/s1476-5586(03)80036-2. View

Khusial P, Vadla B, Krishnan H, Ramlall T, Shen Y, Ichikawa H . Src activates Abl to augment Robo1 expression in order to promote tumor cell migration. Oncotarget. 2011; 1(3):198-209. PMC: 3058788. DOI: 10.18632/oncotarget.126. View

Van Dyck F, Delvaux E, Van de Ven W, Chavez M . Repression of the Transactivating Capacity of the Oncoprotein PLAG1 by SUMOylation. J Biol Chem. 2004; 279(34):36121-31. DOI: 10.1074/jbc.M401753200. View

PERREAU J, Lilienbaum A, Vasseur M, Paulin D . Nucleotide sequence of the human vimentin gene and regulation of its transcription in tissues and cultured cells. Gene. 1988; 62(1):7-16. DOI: 10.1016/0378-1119(88)90575-6. View

Maher E, Furnari F, Bachoo R, Rowitch D, Louis D, Cavenee W . Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001; 15(11):1311-33. DOI: 10.1101/gad.891601. View

10.

Muller S, Ledl A, Schmidt D . SUMO: a regulator of gene expression and genome integrity. Oncogene. 2004; 23(11):1998-2008. DOI: 10.1038/sj.onc.1207415. View

11.

Sontheimer H . Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci. 2003; 26(10):543-9. DOI: 10.1016/j.tins.2003.08.007. View

12.

Nojiri S, Joh T, Miura Y, Sakata N, Nomura T, Nakao H . ATBF1 enhances the suppression of STAT3 signaling by interaction with PIAS3. Biochem Biophys Res Commun. 2004; 314(1):97-103. DOI: 10.1016/j.bbrc.2003.12.054. View

13.

MAHALEY Jr M, Mettlin C, Natarajan N, Laws Jr E, Peace B . National survey of patterns of care for brain-tumor patients. J Neurosurg. 1989; 71(6):826-36. DOI: 10.3171/jns.1989.71.6.0826. View

14.

Singh S, Sadacharan S, Su S, Belldegrun A, Persad S, Singh G . Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. Cancer Res. 2003; 63(9):2306-11. View

15.

Wang L, Banerjee S . Differential PIAS3 expression in human malignancy. Oncol Rep. 2004; 11(6):1319-24. View

16.

Yang H, Lieska N, Shao D, Kriho V, Pappas G . Proteins of the intermediate filament cytoskeleton as markers for astrocytes and human astrocytomas. Mol Chem Neuropathol. 1994; 21(2-3):155-76. DOI: 10.1007/BF02815349. View

17.

Gilles C, Polette M, Zahm J, Tournier J, Volders L, Foidart J . Vimentin contributes to human mammary epithelial cell migration. J Cell Sci. 1999; 112 ( Pt 24):4615-25. DOI: 10.1242/jcs.112.24.4615. View

18.

Gilles C, Polette M, Mestdagt M, Nawrocki-Raby B, Ruggeri P, Birembaut P . Transactivation of vimentin by beta-catenin in human breast cancer cells. Cancer Res. 2003; 63(10):2658-64. View

19.

Knuesel M, Cheung H, Hamady M, Barthel K, Liu X . A method of mapping protein sumoylation sites by mass spectrometry using a modified small ubiquitin-like modifier 1 (SUMO-1) and a computational program. Mol Cell Proteomics. 2005; 4(10):1626-36. DOI: 10.1074/mcp.T500011-MCP200. View

20.

Panicker S, Raychaudhuri B, Sharma P, Tipps R, Mazumdar T, Mal A . p300- and Myc-mediated regulation of glioblastoma multiforme cell differentiation. Oncotarget. 2011; 1(4):289-303. PMC: 3248108. DOI: 10.18632/oncotarget.139. View